Background {#s1}
==========

*Enterobacter aerogenes* is a motile, non-spore forming, Gram-negative bacteria from the *Enterobacteriaceae* family. *Enterobacter* spp. have emerged as multidrug-resistant (MDR) nosocomial bacteria, especially in intensive care units (Loiwal et al., [@B26]; Piagnerelli et al., [@B35]). Therefore, over the last decade *Enterobacter* spp. were included in the ESKAPE group, which also comprises *Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii*, and *Pseudomonas aeruginosa* (Rice, [@B42]; Boucher et al., [@B6]). Further, bloodstream infections with MDR *E. aerogenes* have been associated with high mortality rates (Davin-Regli and Pagés, [@B12]).

Hospital outbreaks due to *E. aerogenes* have been reported in Europe since the mid-1990s and have been related to an epidemic extended-spectrum beta-lactamase (ESBL) clone carrying the *bla*~TEM-24~ gene (Bosi et al., [@B5]; Galdbart et al., [@B18]; Dumarche et al., [@B15]; Salso et al., [@B43]). Constitutive AmpC a (beta-lactamase) overexpression is the major cephalosporin resistance mechanism in *Enterobacter* spp., happening more often than the acquisition of *amp*C genes through the activity of mobile genetic elements (Perez-Perez and Hanson, [@B34]). Further, the increased expression of ESBLs led to the adoption of carbapenems to treat *E. aerogenes* infections (Perez-Perez and Hanson, [@B34]; Davin-Regli and Pagés, [@B12]).

Carbapenems have been considered the antibiotic of choice for treating patients infected with ESBL-producing *Enterobacteriaceae* (Vardakas et al., [@B48]). However, emergence of carbapenem-resistant *E. aerogenes* isolates during carbapenem therapy of hospitalized patients (Chen et al., [@B9]), cases of sepsis due to carbapenem-resistant *E. aerogenes* after liver transplantation (Chen et al., [@B8]) and hospital disseminations of carbapenemase-producing *E. aerogenes* have been recently reported in several countries (Lavigne et al., [@B24]; Kuai et al., [@B22]; Qin et al., [@B40]; Pulcrano et al., [@B39]). Acquisition and expression of carbapenemases constitute the primary mechanism underlying the development of carbapenem resistance (Rapp and Urban, [@B41]). Nevertheless, loss of function mutations in porin genes and increased expression of efflux pumps or their regulators have also been associated with carbapenem resistance profiles (Pradel and Pages, [@B38]; Yigit et al., [@B51]; Bornet et al., [@B4]).

Broad-spectrum antimicrobial-resistant *E. aerogenes* isolates, some resistant to carbapenems (Qin et al., [@B40]) and last-line therapeutic options such as colistin (Diene et al., [@B13]), have been responsible for outbreaks in the United States of America (Wong et al., [@B49]), China (Qin et al., [@B40]), Japan (Goshi et al., [@B19]), France (Diene et al., [@B13]), Fiji (Narayan et al., [@B28]) and Brazil (Tuon et al., [@B47]). However, few reports related to *E. aerogenes* epidemiology, pathogenesis, and molecular characterization have been conducted in Brazil. Recently, five panresistant *E. aerogenes* isolates were reported in a Brazilian teaching hospital, resulting in a high mortality rate (37.5%) among 16 infected patients (Tuon et al., [@B47]). We have observed high prevalence (\>20%) of ESBL-producing *Enterobacteriaceae* spp., in particular *K. pneumoniae* and *E. aerogenes*, in our hospital since 2003 (Nogueira Kda et al., [@B31], [@B30]). Previous molecular characterization studies conducted over 5 years in our hospital showed high prevalence of *bla*~CTX-M2~, ~-M15~, ~-M59~, *bla*~SHV-2~ and *bla*~TEM~ genes in *Enterobacter* spp. isolates (Nogueira Kda et al., [@B31], [@B30]). The presence of *bla*~PER-2~ was also detected in a few isolates (Nogueira Kda et al., [@B31], [@B30]). Given the severity of *E. aerogenes* infections and the urgent need to better understand the genetic basis of multidrug resistance, here we report the whole-genome sequencing and resistance gene repertoire of four multidrug-resistant *E. aerogenes* isolated from hospitalized patients in Brazil.

Methods {#s2}
=======

Sample collection and identification
------------------------------------

*E. aerogenes* isolates C10, D2, D3, and E9 were obtained between 2006 and 2012 from patients hospitalized in wards or intensive care units at the Hospital de Clínicas of the Universidade Federal do Paraná (Curitiba, Brazil). The main selection criterion for genome sequencing was the MDR phenotype, particularly in carbapenem resistant isolates. The negative laboratory tests for carbapenemases were also taken into account, as divergent enzymes or alternative resistance mechanisms could be relevant to the observed MDR phenotypes. C10 and D2 samples were isolated from different body sites of the same patient. Isolates were grown in selective medium with an ertapenem disk (10 ug) and stored at −80°C in trypticase soy broth containing glycerol 15%. Identification of isolates was performed using Vitek® 2 Compact (BioMérieux S.A., Marcy l\'Etoile, France) and by mass spectrometry using Microflex LT instrument (Bruker Daltonics, Bremen, Germany). This study was carried out in accordance with the Brazilian legislation and was approved by the Institutional Ethics Review Board of the Hospital de Clínicas, Universidade Federal do Paraná (IRB\#: 2656.263/2011-11). Our study involved only bacterial isolates and no human specimens were analyzed or stored. Further, we used no patient information other than the anatomical sites from where the isolates were collected. Therefore, the same Ethics Review Board exempted us from obtaining informed consent forms.

Resistance profile analysis
---------------------------

### Antimicrobial susceptibility testing

Isolates were tested by agar dilution against 15 antibiotics according to the Clinical and Laboratory Standard Institute guidelines (CLSI, [@B10]). Minimal inhibitory concentration (MIC) was interpreted as recommended by CLSI standards (CLSI, [@B11]). Polymyxin, tigecycline and fosfomycin breakpoints were interpreted using EUCAST standards (Eucast, [@B17]). Modified Hodge test (MHT), double-disk synergy and hydrolysis assay were performed to determine the carbapenem resistance phenotypes, as previously described (Carvalhaes et al., [@B7]; Eucast, [@B16]).

### Molecular typing and detection of resistance markers

The genetic relatedness of the *E. aerogenes* isolates were determined by pulsed-field gel electrophoresis (PFGE), as described elsewhere (Kaufmann, [@B21]). DNA fingerprints were interpreted as recommended by Tenover et al. ([@B45]). The presence of the *bla*~MOX~, *bla*~CMY~, *bla*~LAT~, *bla*~BIL~, *bla*~DHA~, *bla*~ACC~, *bla*~MIR~, *bla*~ACT~, *bla*~FOX~, *bla*~TEM~, *bla*~SHV~, *bla*~CTX-M1,\ -M2,\ -M8,\ -M9,\ -M25~, *bla*~KPC~, *bla*~GES~, *bla*~IMP~, *bla*~VIM~, *bla*~NDM~, bla~SPM~, bla~GIM~, bla~SIM~, *bla*~OXA-23~, ~-48~, ~-51~, ~-58~, and ~-143~ was tested by PCR as previously described (Payne and Thomson, [@B33]; Poirel et al., [@B36], [@B37]; Perez-Perez and Hanson, [@B34]; Naas et al., [@B27]; Higgins et al., [@B20]; Woodford, [@B50]; Nordmann et al., [@B32]).

Genome sequencing, assembly, and annotation
-------------------------------------------

Genomic DNA was extracted using DNeasy 96 Blood & Tissue Kit (QIAGEN Silicon Valley, Redwood City, USA). DNA quality was assessed using a Bioanalyzer 2100 system (Agilent Technologies, Santa Clara, USA). DNA quantification was performed using Qubit (Thermo Fisher Scientific Inc., Waltham, USA). Illumina sequencing libraries with an average fragment size of 550 bp were prepared using Illumina TruSeq DNA PCR-free LT Kit (Illumina Inc., San Diego, USA). Whole-genome sequencing of paired-end (PE) libraries was performed using a HiSeq 2500 instrument in RAPID run mode (Illumina Inc., San Diego, USA) at the Life Sciences Core Facilities of the State University of Campinas (São Paulo, Brazil). Quality-based trimming and filtering was performed using Trimmomatic version 0.32 (Bolger et al., [@B3]). PE reads were assembled *de novo* using Velvet version 1.2.10 (Zerbino and Birney, [@B53]) and contigs were scaffolded using SSPACE version 3.0 (Boetzer et al., [@B2]). Gene predictions and annotations were performed using NCBI Prokaryotic Genome Automatic Annotation Pipeline (PGAAP; Angiuoli et al., [@B1]).

Identification of antibiotic resistance genes
---------------------------------------------

Antibiotic resistance-related genes were predicted using the ResFinder database version 2.1 (Zankari et al., [@B52]) with the following parameters: "all databases" were used for antimicrobial configuration, type of reads as "assembled genomes/contigs" and thresholds of 98 identity and 80% coverage between sequences. This dataset of resistance genes was complemented with BLASTp searches against the ARDB (Antibiotic Resistance Genes Database) version 1.1 (Liu and Pop, [@B25]) using "resistance gene complete" database, 40% identity and *e*-value of 0.0001.

Results {#s3}
=======

Resistance profiles
-------------------

All isolates showed MDR profile and had increased MIC for at least one carbapenem. Information regarding collection date and site, clinical setting, PFGE profile and antimicrobial resistance profiles of each isolate are available in Table [1](#T1){ref-type="table"}. Among the four analyzed samples, C10 and D2 were isolated from different body sites of the same patient within a short period of time (a month) and belong to the same PFGE profile. These genomes allow one to analyze the possible genome plasticity between the isolates. D3 and E9 samples were isolated from two patients with an interval of collection date greater than 5 years. D3 and E9 were also interesting because of their sensitivity to meropenem and resistance to ertapenem and imipenem. Surprisingly, E9 showed resistance to carbapenems but not to 3rd (ceftazidime and cefotaxime) and 4th generation (cefepime) cephalosporins (Table [1](#T1){ref-type="table"}). All isolates possessed *bla*~AmpC~ and *bla*~TEM~, as detected by PCR. The gene *bla*~CTX-M2~ was found in all isolates except E9. Phenotypic tests (i.e., Modified Hodge test and double-disk synergy) to detect carbapenemases were positive for C10, D2, and E9. However, no class A, B, and D carbapenemase encoding genes were detected by PCR. All isolates tested negative in carbapenem hydrolysis assays.

###### 

**Clinical, phenotypic, molecular data, and genomic features of the four ***Enterobacter aerogenes*** isolates reported in the present work**.

  **Sample ID**                                 ***E. aerogenes* C10**                   ***E. aerogenes* D2**                    ***E. aerogenes* D3**                    ***E. aerogenes* E9**
  --------------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- -------------------------------------
  **CLINICAL DATA**                                                                                                                                                        
  Date of isolation                             09.28.2007                               10.12.2007                               12.12.2006                               01.31.2012
  Clinic                                        Ward                                     Ward                                     Ward                                     ICU[^b^](#TN2){ref-type="table-fn"}
  Source                                        Blood                                    Catheter tip                             BAL[^a^](#TN1){ref-type="table-fn"}      Urine
  **MINIMAL INHIBITORY CONCENTRATION (mg/L)**                                                                                                                              
  Amicacin                                      **64**                                   **64**                                   **64**                                   **64**
  Gentamicin                                    **\>64**                                 **\>64**                                 **\>64**                                 2
  Ceftazidime                                   **16**                                   **32**                                   **16**                                   0.5
  Cefepime                                      **128**                                  **\>128**                                **128**                                  0.5
  Cefotaxime                                    **\>128**                                **128**                                  **128**                                  0.5
  Ertapenem                                     **32**                                   **32**                                   **16**                                   **2**
  Imipenem                                      **8**                                    **8**                                    **32**                                   **8**
  Meropenem                                     **8**                                    **8**                                    2                                        0.5
  Polimyxin                                     0.25                                     0.25                                     0.5                                      0.25
  Ciprofloxacin                                 **\>16**                                 **\>16**                                 **16**                                   2
  Levofloxacin                                  **\>8**                                  **8**                                    **\>8**                                  0.25
  Tigecycline                                   2                                        2                                        1                                        0.5
  Doxycycline                                   **16**                                   **16**                                   **64**                                   8
  Minocycline                                   8                                        8                                        8                                        2
  Fosfomycin                                    **256**                                  **256**                                  **\>512**                                **64**
  **MOLECULAR FEATURES**                                                                                                                                                   
  PFGE profile                                  A                                        A1                                       B                                        C
  *bla* genes                                   *bla*~AmpC~, *bla*~TEM~, *bla*~CTX−M2~   *bla*~AmpC~, *bla*~TEM~, *bla*~CTX−M2~   *bla*~AmpC~, *bla*~TEM~, *bla*~CTX−M2~   *bla*~AmpC~, *bla*~TEM~
  **GENOMIC FEATURES**                                                                                                                                                     
  Estimate genome size (bp)                     5,833,521                                5,821,782                                5,584,745                                5,637,471
  Genome coverage                               208x                                     182x                                     137x                                     197x
  Number of scaffolds                           58                                       57                                       55                                       59
  N50 (bp)                                      505,999                                  464,022                                  505,714                                  461,836
  Number of paired-end reads used               14,346,552                               12,939,780                               9,406,438                                12,891,456
  %GC                                           53.61                                    53.63                                    53.69                                    53.67
  Predicted genes                               5,636                                    5,622                                    5,311                                    5,402
  Predicted protein-coding genes                5,363                                    5,380                                    5,067                                    5,129
  tRNAs                                         82                                       80                                       83                                       85
  rRNAs (5S, 16S, 23S)                          9, 5, 16                                 6, 3, 8                                  8, 4, 9                                  8, 10, 13
  ncRNAs                                        12                                       12                                       13                                       12
  Pseudogenes                                   149                                      133                                      127                                      145

*Numbers in bold indicate resistance to a given antibiotic*.

Bronchoalveolar lavage (BAL) and

*Intensive care unit (ICU)*.

Genomic features
----------------

We obtained between 16,841,714 and 25,138,390 150 bp PE reads per library. After genome assembly, 5,833,521 bp were assembled in 58 scaffolds for C10, 5,821,782 bp were assembled in 57 scaffolds for D2, 5,584,745 bp were assembled in 55 scaffolds for D3 and 5,637,471 bp were assembled in 59 scaffolds for E9. By using the NCBI Prokaryotic Annotation Pipeline, we were able to predict 5,363, 5,380, 5,067, and 5,129 protein-coding sequences in each of the genomes listed above, respectively. Genomic features of the four sequenced genomes are summarized in Table [1](#T1){ref-type="table"}.

Antibiotic resistance genes
---------------------------

A total of 18 enzymes related to antibiotic resistance were identified using ResFinder, ARDB and PGAAP (Table [2](#T2){ref-type="table"}). All isolates harbor genes related to: (i) aminoglycoside resistance (genes *aacA4* and *aadA*); (ii) beta-lactam resistance, including genes belonging to class A beta-lactamases (TEM family), class B beta-lactamases (Ribonuclease Z), class C beta-lactamases (CMY/LAT/MOX/ACT/MIR/FOX family) and class D beta-lactamases (OXA-9); (iii) bacitracin resistance (gene *bacA*), and (iv) sulphonamide resistance (gene *sul1*; Table [2](#T2){ref-type="table"}). Genes *sul2* and *rmtD* were only identified in *E. aerogenes* D3. The gene *sul2* has been implicated on sulphonamide resistance for inducing high expression levels of the enzyme dihydropteroate synthase (Sköld, [@B44]), while *rmtD* has been related to aminoglycoside resistance and this variant was identified for the first time in South America in a *P. aeruginosa* isolate in 2005 (Doi et al., [@B14]). Interestingly, *E. aerogenes* D3 was isolated in 2006, indicating that this variant has spread amongst *Enterobacteriaceae* in Brazil since its first report (Doi et al., [@B14]).

###### 

**Resistance gene repertoire identified using ResFinder, ARDB, and NCBI annotation pipeline**.

  **Protein**                                                                                                          **Reference Sequence**                                              **C10**                   **D2**                    **D3**                    **E9**
  -------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------- ------------------------- ------------------------- ------------------------- -------------------------
  **ENZYMES**                                                                                                                                                                                                                                                            
  16S rRNA (adenine(1518)-N(6)/adenine(1519)-N(6))-dimethyltransferase (KsgA)                                          [WP_003829609.1](WP_003829609.1)                                    AW170_18245               AYK88_16575               A1Q75_18030               A1J85_13160
  16S rRNA (guanine(1405)-N(7))-methyltransferase RmtD                                                                 [WP_019726361.1](WP_019726361.1)                                    --                        --                        A1Q75_26170               --
  AacA4 family aminoglycoside N(6\')-acetyltransferase (AacA4)                                                         [WP_014839929.1](WP_014839929.1) [P19650.1](P19650.1)               AW170_26985               AYK88_26865 AYK88_26940   A1Q75_26315               A1J85_26740
  Aminoglycoside N(3)-acetyltransferase III (AacC3)                                                                    [P0A255.1](P0A255.1)                                                AW170_26910               AYK88_26960               --                        --
  ANT(3″)-Ia family aminoglycoside nucleotidyltransferase AadA                                                         [WP_014325834.1](WP_014325834.1)                                    AW170_26955               AYK88_26945               A1Q75_26045 A1Q75_26310   A1J85_26670 A1J85_26735
  Chloramphenicol acetyltransferase III (Cat3)                                                                         [P00484.1](P00484.1)                                                AW170_27070               AYK88_27075               --                        --
  Class A beta-lactamase - Beta-lactamase CTX-M-6                                                                      [O65976.1](O65976.1)                                                AW170_27050               AYK88_27040               A1Q75_26225               --
  Class A beta-lactamase - TEM family                                                                                  [WP_010331504.1](WP_010331504.1) [WP_000027063.1](WP_000027063.1)   AW170_26915 AW170_27230   AYK88_27065 AYK88_27140   A1Q75_26300               A1J85_24665 A1J85_26820
  Class A beta-lactamase - TEM family                                                                                  [WP_001398207.1](WP_001398207.1)                                    AW170_26970               --                        --                        --
  Class B beta-lactamase - Ribonuclease Z (metallo-beta-lactamase superfamily)                                         [WP_004890624.1](WP_004890624.1)                                    AW170_13355               AYK88_10035               A1Q75_10920               A1J85_17515
  Class C beta-lactamase - CMY/LAT/MOX/ACT/MIR/FOX family                                                              [WP_008453751.1](WP_008453751.1)                                    AW170_05580               AYK88_04475               A1Q75_09705               A1J85_14245
  Class D beta-lactamase - Beta-lactamase OXA-2                                                                        [P0A1V8.1](P0A1V8.1)                                                AW170_26980               AYK88_26870               --                        --
  Class D beta-lactamase - oxacillinase-carbenicillinase (OXA-9)                                                       [WP_004153119.1](WP_004153119.1)                                    AW170_26960               AYK88_26950               A1Q75_26305               A1J85_26730
  Dihydropteroate synthase type-1 (SulI)                                                                               [P0C002.1](P0C002.1)                                                AW170_27105               AYK88_26880               A1Q75_26340               A1J85_26680
  Sulfonamide-resistant dihydropteroate synthase Sul2                                                                  [WP_001043267.1](WP_001043267.1)                                    --                        --                        A1Q75_26185               --
  Trimethoprim-resistant dihydrofolate reductase DfrA                                                                  [WP_001611015.1](WP_001611015.1)                                    --                        --                        A1Q75_26055               A1J85_26660
  Undecaprenyl-diphosphatase (BacA)                                                                                    [WP_012907642.1](WP_012907642.1)                                    AW170_01035               AYK88_19635               A1Q75_21735               A1J85_01030
  Qnr family quinolone resistance pentapeptide repeat protein                                                          [WP_017111199.1](WP_017111199.1)                                    AW170_27090               AYK88_27095               A1Q75_26320               --
  **TRANSPORTERS**                                                                                                                                                                                                                                                       
  Aminoglycoside/multidrug transporter subunit AcrD                                                                    [WP_005121895.1](WP_005121895.1)                                    AW170_13975               AYK88_09410               A1Q75_11550               A1J85_16890
  Bcr/CflA family multidrug efflux MFS transporter                                                                     [WP_004202891.1](WP_004202891.1)                                    AW170_03270               AYK88_06790               A1Q75_02780               A1J85_21475
  Bcr/CflA family multidrug efflux MFS transporter                                                                     [WP_008804003.1](WP_008804003.1)                                    AW170_13100               AYK88_10285               A1Q75_10670               A1J85_23465
  Chloramphenicol efflux MFS transporter CmlA5                                                                         [WP_012300772.1](WP_012300772.1)                                    --                        --                        A1Q75_26050               A1J85_26665
  Macrolide ABC transporter permease/ATP-binding protein MacB                                                          [WP_004147781.1](WP_004147781.1)                                    AW170_08470               AYK88_01580               A1Q75_06815               A1J85_05705
  Macrolide transporter subunit MacA                                                                                   [WP_008805838.1](WP_008805838.1)                                    AW170_08465               AYK88_01585               A1Q75_06820               A1J85_05700
  MATE family efflux transporter, multidrug efflux protein                                                             [WP_003857645.1](WP_003857645.1)                                    AW170_03255               AYK88_06805               A1Q75_02765               A1J85_21460
  Membrane protein, Multidrug resistance efflux pump EmrA                                                              [WP_009307711.1](WP_009307711.1)                                    AW170_03350               AYK88_06710               A1Q75_02860               A1J85_21555
  MexE family multidrug efflux RND transporter periplasmic adaptor                                                     [WP_004121017.1](WP_004121017.1)                                    AW170_01795               AYK88_08270               A1Q75_01550               A1J85_20240
  MexE family multidrug efflux RND transporter periplasmic adaptor subunit, multidrug efflux system transporter AcrA   [WP_004129915.1](WP_004129915.1) [WP_015585499.1](WP_015585499.1)   AW170_06375 AW170_10590   AYK88_03675 AYK88_11425   A1Q75_08905 A1Q75_13105   A1J85_15040 A1J85_10280
  MexX family efflux pump subunit, multidrug efflux system transporter AcrA                                            [WP_014906857.1](WP_014906857.1)                                    AW170_00035               AYK88_20640               A1Q75_20735               A1J85_00030
  Multidrug ABC transporter ATP-binding protein                                                                        [WP_000422210.1](WP_000422210.1)                                    AW170_13185               AYK88_10200               A1Q75_10755               A1J85_23550
  Multidrug efflux RND transporter permease subunit                                                                    [WP_004901494.1](WP_004901494.1)                                    AW170_10595               AYK88_11430               A1Q75_13110               A1J85_10285
  Multidrug efflux RND transporter permease subunit OqxB                                                               [WP_015367127.1](WP_015367127.1)                                    AW170_01800               AYK88_08265               A1Q75_01555               A1J85_20245
  Multidrug efflux RND transporter permease subunit, multidrug efflux protein AcrB                                     [WP_017899940.1](WP_017899940.1) [WP_015571248.1](WP_015571248.1)   AW170_00030 AW170_06370   AYK88_20645 AYK88_03680   A1Q75_20730 A1Q75_08910   A1J85_00025 A1J85_15035
  Multidrug resistance protein D (EmrD)                                                                                [WP_008806760.1](WP_008806760.1)                                    AW170_10405               AYK88_11240               A1Q75_12920               A1J85_10095
  Multidrug resistance protein MdtB                                                                                    [WP_020244584.1](WP_020244584.1)                                    AW170_12610               AYK88_10840               A1Q75_10110               A1J85_23005
  Multidrug resistance protein MdtC                                                                                    [Q7ACM1.1](Q7ACM1.1)                                                AW170_12615               AYK88_10845               A1Q75_10105               A1J85_23000
  Multidrug resistance protein MdtH                                                                                    [WP_017900739.1](WP_017900739.1)                                    AW170_09790               AYK88_00255               A1Q75_01100               A1J85_19845
  Multidrug transporter, multidrug efflux system protein EmrA                                                          [WP_009308476.1](WP_009308476.1)                                    AW170_15715               AYK88_14045               A1Q75_16525               A1J85_03195
  Outer membrane channel protein TolC                                                                                  [WP_015369648.1](WP_015369648.1)                                    AW170_01095               AYK88_19575               A1Q75_21795               A1J85_01090
  Outer membrane component of tripartite multidrug resistance system, putative outer membrane efflux protein MdtP      [WP_015369857.1](WP_015369857.1)                                    AW170_16750               AYK88_15075               A1Q75_15485               A1J85_02150
  QacE family quaternary ammonium compound efflux SMR transporter                                                      [WP_000679416.1](WP_000679416.1)                                    AW170_27110               AYK88_26875               A1Q75_26335               A1J85_26675
  Quaternary ammonium compound-resistance protein SugE                                                                 [WP_001597468.1](WP_001597468.1)                                    AW170_19990               AYK88_18310               A1Q75_19995               A1J85_18375
  Tetracycline efflux MFS transporter Tet(D)                                                                           [WP_001039466.1](WP_001039466.1)                                    --                        --                        A1Q75_26055               \-

Although the four isolates showed carbapenem-resistance, no carbapenemase gene was identified using molecular detection or *in silico* analysis. Hence, it is likely that these isolates employ alternative mechanisms to counter carbapenem effects. Various multidrug efflux transporters were found in the genomes described here (Table [2](#T2){ref-type="table"}). They belong to four superfamilies: the major facilitator superfamily (MFS), multidrug and toxic compound extrusion (MATE), ATP-binding cassette (ABC) and resistance-nodulation-cell division (RND). RND type of transporters has been often associated with multidrug resistance of Gram-negative bacteria (Nikaido, [@B29]). In particular, the RND type genes forming the AcrA-AcrB-TolC efflux pump were found in multiple copies in our isolates (Table [2](#T2){ref-type="table"}). Experimental evolution studies of *E. aerogenes* under successive imipenem exposure reported alterations in membrane permeability with complete loss of porins (e.g., Omp35 and Omp36) and overexpression of AcrAB-TolC efflux pumps (Bornet et al., [@B4]; Thiolas et al., [@B46]; Lavigne et al., [@B23]). As a result of efflux pump expression, the *E. aerogenes* isolates showed resistance to carbapenems and other antibiotics, especially fluoroquinolones (Bornet et al., [@B4]; Thiolas et al., [@B46]; Lavigne et al., [@B23]). Given the multiple copies of genes encoding efflux pumps in our isolates, it is possible that an increased expression of AcrAB-TolC efflux pumps could contribute to the observed carbapenem-resistant profiles.

*E. aerogenes* is an emergent nosocomial pathogen with a diversity of mechanisms to circumvent antimicrobial activity. Here we reported the phenotypic screens, genome sequencing, and prediction of putative resistance gene repertoires of four multidrug-resistant *E. aerogenes* isolated between 2006 and 2012. The data reported here may help understand the biochemistry, evolution, and epidemiology of this important pathogen. The material provided in this work may be used in future comparative genomics and molecular epidemiology studies aiming to clarify the resistance profiles and dynamics of multidrug-resistant *Enterobacteriaceae* species.
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